Cited by 222Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 89 of the 91 references it cites were found in a registry or an index.

Rodent models for Alzheimer’s disease drug discovery

Open access

Puzzo, Daniela, Gulisano, Walter, Palmeri, Agostino, Arancio, Ottavio·2015·Expert Opinion on Drug Discovery

DOI 10.1517/17460441.2015.1041913PMC PMC4592281

Open this paper in CoChat — free account

Abstract

INTRODUCTION: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss and personality changes, leading to dementia. Histopathological hallmarks are represented by aggregates of beta-amyloid peptide (Aβ) in senile plaques and deposition of hyperphosphorylated tau protein in neurofibrillary tangles in the brain. Rare forms of early onset familial Alzheimer's disease are due to gene mutations. This has prompted researchers to develop genetically modified animals that could recapitulate the main features of the disease. The use of these models is complemented by non-genetically modified animals. AREAS COVERED: This review summarizes the characteristics of the most used transgenic (Tg) and non-Tg models of AD. The authors have focused on models mainly used in their laboratories including amyloid precursor protein (APP) Tg2576, APP/presenilin 1, 3xAD, single h-Tau, non-Tg mice treated with acute injections of Aβ or tau, and models of physiological aging. EXPERT OPINION: Animal models of disease might be very useful for studying the pathophysiology of the disease and for testing new therapeutics in preclinical studies but they do not reproduce the entire clinical features of human AD. When selecting a model, researchers should consider the various factors that might influence the phenotype. They should also consider the timing of testing/treating animals since the age at which each model develops certain aspects of the AD pathology varies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1517/17460441.2015.1041913

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“Neuronal loss, potentially due to intraneuronal Ab accumulation [59], has been found in a 5XTg mouse model containing APP (Swedish K670N/M671L, Florida I716V, and London V717I) and PSEN1 (M146L and L286V) mutations.”
Background
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1
Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C.-M., Pérez‐Tur, J., Hutton, M., Buée, L., Harigaya, Y., Yager, D., et al. (1996) · Nature · doi:10.1038/383710a0 · Cited by 1,486
Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio In Vitro and In Vivo
Borchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C.-M., Kim, G., Seekins, S., Yager, D., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80230-5 · Cited by 1,478
Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes
Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386
Intraneuronal Aβ Causes the Onset of Early Alzheimer’s Disease-Related Cognitive Deficits in Transgenic Mice
Billings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., & LaFerla, F. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.040 · Cited by 1,294

Show all 91 references

Research works printed but not linked: 5

Alzheimer A, 1906, Neurol Centralblatt, 23, 1129
10.1037/0735-7044.113.5.982 · DOI
Li H, 2015, Neurobiol Aging
Moe JG, 2008, Evaluation of the effect of extracellular tau oligomers on synaptic function
Moe JG, 2010, Validation of extracellular tau oligomer target for drug discovery in a novel animal model

Sorted by citations

Items 101–200 of 219

Experimental Pharmacology in Transgenic Rodent Models of Alzheimer’s Disease
Cuello, A. C., Hall, H., & Carmo, S. D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00189 · Cited by 21
Using model systems to understand errant plasticity mechanisms in psychiatric disorders
Averbeck, B. B., & Chafee, M. V. (2016) · Nature Neuroscience · doi:10.1038/nn.4413 · Cited by 18
Locomotor activity, emotionality, sensori-motor gating, learning and memory in the APPswe/PS1dE9 mouse model of Alzheimer’s disease
O’Leary, T. P., Hussin, A. T., Gunn, R. K., & Brown, R. E. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.05.021 · Cited by 18
Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease
Ameen, T. B., Ali, U., Salma, O., Samee, M. A., Abbas, S. M. I., Kashif, S. N., Arifi, M. A., Ali, M., Khowaja, M., Ali, S. M. S., et al. (2025) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-025-00968-3 · Cited by 20
A systems biology-led insight into the role of the proteome in neurodegenerative diseases
Fasano, M., Monti, C., & Alberio, T. (2016) · Expert Review of Proteomics · doi:10.1080/14789450.2016.1219254 · Cited by 17
From Reproducibility to Translation in Neurodegenerative Disease
Zeiss, C. J. (2017) · ILAR Journal · doi:10.1093/ilar/ilx006 · Cited by 18
Severe Gestational Low-Protein Intake Impacts Hippocampal Cellularity, Tau, and Amyloid-β Levels, and Memory Performance in Male Adult Offspring: An Alzheimer-Simile Disease Model?
Grigoletti-Lima, G. B., Lopes, M. G., Franco, A. T. B., Damico, A. M., Boer, P. A., & Gontijo, J. A. R. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210297 · Cited by 16
The use of human neurons for novel drug discovery in dementia research
Vargas‐Caballero, M., Willaime‐Morawek, S., Gómez‐Nicola, D., Perry, V. H., Bulters, D. O., & Mudher, A. K. (2016) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1154528 · Cited by 15
Cortical tau burden and behavioural dysfunctions in mice exposed to monosodium glutamate in early life
Hassaan, P. S., Dief, A. E., Zeitoun, T. M., Baraka, A., Deacon, R. M. J., & Elshorbagy, A. K. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220720 · Cited by 15
What is the gold standard model for Alzheimer’s disease drug discovery and development?
Cacabelos, R., Carrera, I., Martínez-Iglesias, O. A., Cacabelos, N., & Naidoo, V. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1960502 · Cited by 15
Characterization of Early Alzheimer’s Disease-Like Pathological Alterations in Non-Human Primates with Aging: A Pilot Study
Jester, H. M., Gosrani, S. P., Ding, H., Zhou, X., Ko, M., & Ma, T. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215303 · Cited by 15
Hyperactivity of medial prefrontal cortex pyramidal neurons occurs in a mouse model of early-stage Alzheimer’s disease without β-amyloid accumulation
Choudhury, N., Chen, L., Al‐Harthi, L., & Hu, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1194869 · Cited by 15
Rodent Models for Alzheimer’s Disease in Drug Discovery
Barrett, J. E., & McGonigle, P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802810-0.00012-x · Cited by 15
Network-Driven Proteogenomics Unveils an Aging-Related Imbalance in the Olfactory IκBα-NFκB p65 Complex Functionality in Tg2576 Alzheimer’s Disease Mouse Model
Alonso, M. P., Lachén‐Montes, M., González-Morales, A., Ausín, K., Pérez‐Mediavilla, A., Fernández‐Irigoyen, J., & Santamaría, E. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112260 · Cited by 15
Fatty‐acid amide hydrolase inhibition mitigates Alzheimer's disease progression in mouse models of amyloidosis
Oddi, S., Scipioni, L., Totaro, A., Giacovazzo, G., Ciaramellano, F., Tortolani, D., Leuti, A., Businaro, R., Armeli, F., Bilkei‐Gorzó, A., et al. (2025) · FEBS Journal · doi:10.1111/febs.17403 · Cited by 14
Early-Onset Molecular Derangements in the Olfactory Bulb of Tg2576 Mice: Novel Insights Into the Stress-Responsive Olfactory Kinase Dynamics in Alzheimer’s Disease
Lachén‐Montes, M., González-Morales, A., Alonso, M. P., Ausín, K., Gómez-Ochoa, M., Zelaya, M. V., Ferrer, I., Pérez‐Mediavilla, A., Fernández‐Irigoyen, J., & Santamaría, E. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00141 · Cited by 16
Discoveries and future significance of research into amyloid-beta/α7-containing nicotinic acetylcholine receptor (nAChR) interactions
Whiteaker, P., & George, A. A. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106743 · Cited by 14
Pterostilbene attenuates amyloid-β induced neurotoxicity with regulating PDE4A-CREB-BDNF pathway.
Meng, J., Chen, Y., Bi, F., Li, H., Chang, C., & Liu, W. (2019) · Europe PMC (PubMed Central) · Cited by 14
Survival Bias, Non-Lineal Behavioral and Cortico-Limbic Neuropathological Signatures in 3xTg-AD Mice for Alzheimer’s Disease from Premorbid to Advanced Stages and Compared to Normal Aging
Muntsant-Soria, A., Castillo-Ruiz, M. D. M., & Giménez‐Llort, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813796 · Cited by 14
The impact of genetics on future drug discovery in schizophrenia
Matsumoto, M., Walton, N. M., Yamada, H., Kondo, Y., Marek, G. J., & Tajinda, K. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1324419 · Cited by 13
Dimeric Tacrine(10)-hupyridone as a Multitarget-Directed Ligand To Treat Alzheimer’s Disease
Xuan, Z., Gu, X., Yan, S., Xie, Y., Zhou, Y., Zhang, H., Jin, H., Hu, S., Mak, S., Zhou, D., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00182 · Cited by 13
Anti-Inflammatory Gene Therapy Improves Spatial Memory Performance in a Mouse Model of Alzheimer’s Disease
Yoo, T. J. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215270 · Cited by 14
The three sisters of fate: Genetics, pathophysiology and outcomes of animal models of neurodegenerative diseases
Klonarakis, M., Vos, M. D., Woo, E. K., Ralph, L. T., Thacker, J. S., & Gil‐Mohapel, J. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104541 · Cited by 14
Elaboration of the Effective Multi-Target Therapeutic Platform for the Treatment of Alzheimer’s Disease Based on Novel Monoterpene-Derived Hydroxamic Acids
Aleksandrova, Y. R., Munkuev, A. A., Mozhaitsev, E. S., Суслов, Е. В., Tsypyshev, D. O., Chaprov, K., Бегунов, Р. С., Volcho, K. P., Salakhutdinov, N. F., & Неганова, М. Е. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119743 · Cited by 14
Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics
Griñán‐Ferré, C., Jarné‐Ferrer, J., Bellver‐Sanchís, A., Codony, S., Puigoriol‐Illamola, D., Sanfeliu, C., Oh, Y., Lee, S., Vázquez, S., & Pallàs, M. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14511 · Cited by 14
Modeling tau pathology in human stem cell derived neurons
Wray, S. (2017) · Brain Pathology · doi:10.1111/bpa.12521 · Cited by 14
Porphyromonas gingivalis Impairs Microglial Aβ Clearance in a Mouse Model
Xie, M., Huang, X., Tang, Q., Yu, S., Zhang, K., Lu, X., Zhang, Y., Wang, J., Zhang, L., & Chen, L. (2025) · Journal of Dental Research · doi:10.1177/00220345241294009 · Cited by 12
Alzheimer's disease, a metabolic disorder: Clinical advances and basic model studies (Review)
Zhou, S., Tu, L., Chen, W., Yan, G., Guo, H., Wang, X., Hu, Q., Liu, H., & Li, F. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12351 · Cited by 12
Genes of susceptibility to early neurodegenerative changes in the rat retina and brain: analysis by means of congenic strains
Korbolina, E. E., Александровна, Ж. А., Фурсова, А. Ж., Kozhevnikova, O. S., & Kolosova, N. G. (2016) · BMC Genetics · doi:10.1186/s12863-016-0461-7 · Cited by 12
Pre-plaque Aß-Mediated Impairment of Synaptic Depotentiation in a Transgenic Rat Model of Alzheimer’s Disease Amyloidosis
Qi, Y., Klyubin, I. V., Hu, N., Ondrejčák, T., & Rowan, M. J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00861 · Cited by 12
Discovery of Novel Drug Candidates for Alzheimer’s Disease by Molecular Network Modeling
Zhou, J., Li, Q., Wu, W., Zhang, X., Zuo, Z., Lu, Y., Zhao, H., & Wang, Z. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.850217 · Cited by 12
Mammalian Models in Alzheimer’s Research: An Update
Sharma, H., Chang, K., Hulme, J., & An, S. S. A. (2023) · Cells · doi:10.3390/cells12202459 · Cited by 12
The contribution of transgenic and nontransgenic animal models in Alzheimer’s disease drug research and development
Mhillaj, E., Cuomo, V., & Mancuso, C. (2017) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000296 · Cited by 11
Animal Models for the Study of Human Neurodegenerative Diseases
Colpo, G. D., Ribeiro, F. M., Rocha, N. P., & Teixeira, A. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809468-6.00042-5 · Cited by 12
Nuclear factor‐kappa B: Glucocorticoid‐induced leucine zipper interface analogs suppress pathology in an Alzheimer's disease model
Srinivasan, M., Lahiri, N. K., Thyagarajan, A., Witek, E., Hickman, D. L., & Lahiri, D. K. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.04.004 · Cited by 11
Animal models of cognitive aging and circuit-specific vulnerability
Burke, S. N., & Foster, T. C. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00002-9 · Cited by 11
Alterations of endocannabinoid signaling and microglia reactivity in the retinas of AD ‐like mice precede the onset of hippocampal β‐amyloid plaques
Tisi, A., Scipioni, L., Carozza, G., Re, L. D., Cimino, G., Meo, C. D., Palaniappan, S., Valle, F., Fanti, F., Giacovazzo, G., et al. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16256 · Cited by 10
Mutations of Histidine 13 to Arginine and Arginine 5 to Glycine Are Responsible for Different Coordination Sites of Zinc(II) to Human and Murine Peptides
Aliès, B., Borghesani, V., Noël, S., Sayen, S., Guillon, E., Testemale, D., Faller, P., & Hureau, C. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201802759 · Cited by 10
Alzheimer’s Disease Drug Development: A Research and Development Ecosystem
Cummings, J. L., Kinney, J. W., & Fillit, H. M. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759.002 · Cited by 10
In Vivo MRI of Amyloid Plaques in a Cholesterol-Fed Rabbit Model of Alzheimer’s Disease
Chen, Y., Lim, P. H., Rogers, K. A., Rutt, B. K., & Ronald, J. A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180207 · Cited by 10
Mitochondria‐associated endoplasmic reticulum membranes: At the crossroad between familiar and sporadic Alzheimer's disease
Wang, K., & Zhang, W. (2021) · Synapse · doi:10.1002/syn.22196 · Cited by 11
Understanding monocyte-driven neuroinflammation in Alzheimer’s disease using human cortical organoid microphysiological systems
Tian, C., Ao, Z., Cerneckis, J., Cai, H., Chen, L., Niu, H., Takayama, K., Kim, J., Shi, Y., Gu, M., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu2708 · Cited by 9
Alzheimer's Disease Drug Development
(2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759 · Cited by 9
Possible Role of Chitin-Like Proteins in the Etiology of Alzheimer’s Disease
Lomiguen, C. M., Vidal, L., Kozlowski, P. B., Prancan, A., & Stern, R. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180326 · Cited by 9
Translational Scoring of Candidate Treatments for Alzheimer’s Disease: A Systematic Approach
Cummings, J. L. (2020) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000507569 · Cited by 9
Critical Review of the Alzheimer’s Disease Non-Transgenic Models: Can They Contribute to Disease Treatment?
Flores-Cuadra, J. A., Madrid, A., Fernández, P. L., Perez-Lao, A. R., Oviedo, D. C., Britton, G. B., & Carreira, M. B. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200870 · Cited by 9
Triptolide injection reduces Alzheimer's disease‐like pathology in mice
Mao, R., Xu, S., Sun, G., Yu, Y., Zuo, Z., Wang, Y., Yang, K. Y., Zhang, Z., & Yang, W. (2023) · Synapse · doi:10.1002/syn.22261 · Cited by 8
Animal Models of Alzheimer’s Disease
Amram, S., & Frenkel, D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803690-7.00003-x · Cited by 8
A novel inducible animal model for studying chronic plasmalogen deficiency associated with Alzheimer’s disease
Smith, T. M., Knudsen, K. J., & Ritchie, S. A. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149132 · Cited by 7
Rethinking early Alzheimer’s disease: An impaired internal model updating disorder?
Antonioni, A. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106790 · Cited by 8
Age‐related synaptic dysfunction in Tg2576 mice starts as a failure in early long‐term potentiation which develops into a full abolishment of late long‐term potentiation
Fernández‐Fernández, D., Dorner‐Ciossek, C., Kroker, K. S., & Rosenbrock, H. (2015) · Journal of Neuroscience Research · doi:10.1002/jnr.23701 · Cited by 7
Tracking human neurologic disease status in mouse brain/plasma using reporter-tagged, EV-associated biomarkers
Maalouf, K., Vaine, C. A., Frederick, D. M., Yoshinaga, A., Obuchi, W., Mahjoum, S., Nieland, L., Ali, J. A., Bragg, D. C., Breakefield, X. O., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.05.011 · Cited by 7
Neurodegeneration Caused by Accumulation of an Oxidized Base Lesion, 8-oxoguanine, in Nuclear and Mitochondrial DNA: From Animal Models to Human Diseases
Nakabeppu, Y. (2016) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814719735_0015 · Cited by 7
Sex-dependent sensitivity to positive allosteric modulation of GABA action in an APP knock-in mouse model of Alzheimer's disease: Potential epigenetic regulation
Auta, J., Locci, A., Guidotti, A., Davis, J. M., & Dong, H. (2021) · Current Research in Neurobiology · doi:10.1016/j.crneur.2021.100025 · Cited by 8
Identification of Structural Calcium Binding Sites in Membrane-Bound Presenilin 1 and 2
Mehra, R., & Kepp, K. P. (2020) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c01712 · Cited by 7
Longitudinal Studies on Alzheimer Disease Mouse Models with Multiple Tracer PET/CT: Application of Reduction and Refinement Principles in Daily Practice to Safeguard Animal Welfare during Progressive Aging
Palumbo, G., Kunze, L. H., Oos, R., Wind-Mark, K., Lindner, S., von Ungern‐Sternberg, B., Bartenstein, P., Ziegler, S. I., & Brendel, M. (2023) · Animals · doi:10.3390/ani13111812 · Cited by 7
Pharmacological inhibition of PLK2 kinase activity mitigates cognitive decline but aggravates APP pathology in a sex-dependent manner in APP/PS1 mouse model of Alzheimer's disease
Martínez-Drudis, L., Bérard, M., Musiol, D., Rivest, S., & Oueslati, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39571 · Cited by 6
Using Single-Cell RNA sequencing with Drosophila, Zebrafish, and mouse models for studying Alzheimer’s and Parkinson’s disease
Lau, F., Binacchi, R., Brugnara, S., Cumplido-Mayoral, A., Savino, S. D., Khan, I., Orso, A., Sartori, S., Bellosta, P., Carl, M., et al. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.03.042 · Cited by 6
The Wnt/β-catenin signaling pathway affects the distribution of cytoskeletal proteins in Aβ treated PC12 cells
Tian, Z.-F., Zhang, X., Zhao, Z., Zhang, F.-H., & Deng, T.-X. (2019) · Journal of Integrative Neuroscience · doi:10.31083/j.jin.2019.03.168 · Cited by 6
A Comprehensive Review on Preclinical Alzheimer's Disease Models: Evaluating their Clinical Relevance
Kushwaha, V., & Sahu, K. K. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010331845240802073645 · Cited by 5
Using Zebrafish Models to Study Epitranscriptomic Regulation of CNS Functions
Jiang, J., Zhang, Y., Wang, J., Qin, Y., Zhao, C., He, K., Wang, C., Liu, Y., Feng, H., Cai, H., et al. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.16311 · Cited by 5
Ontogenetic and Phylogenetic Approaches for Studying the Mechanisms of Cognitive Dysfunctions
Zhuravin, I. A., Dubrovskaya, N. M., Tumanova, N. L., Vasilev, D. S., & Nalivaeva, N. N. (2018) · InTech eBooks · doi:10.5772/intechopen.73666 · Cited by 5
Experimental Models in Neurodegenerative Diseases
Korkmaz, Ü., & Kaya, M. (2019) · Nuclear Medicine Seminars · doi:10.4274/nts.galenos.2019.0009 · Cited by 5
Unraveling the Gordian knot: genetics and the troubled road to effective therapeutics for Alzheimer’s disease
Restifo, L. L. (2021) · Genetics · doi:10.1093/genetics/iyab185 · Cited by 5
MAMs and Mitochondrial Quality Control: Overview and Their Role in Alzheimer’s Disease
Luo, J.-S., Zhai, W.-H., Ding, L.-L., Zhang, X.-J., Han, J., Ning, J., Chen, X.-M., Jiang, W., Yan, R., & Chen, M. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04205-w · Cited by 4
A mass-producible macaque model displays a durable Alzheimer-like cognitive deficit and hallmark amyloid-β/tau/neurofilament light chain pathologies
He, F., Shi, W.-J., Liu, W., Fan, J.-X., He, Z., Zhang, Y., Xiao, J., Ruan, W., Gai, Y., Zhang, H., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251334316 · Cited by 4
BDNF gene therapy rescues neuronal function via unique and common transcriptional responses in Aβ and tau-driven Alzheimer's disease mouse models
Tang, S., Luo, W., Cheng, C., Shen, L., Wu, X., & Xiao, X. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102089 · Cited by 4
Advancements and Challenges in Preclinical Study Models of Neurodegenerative Brain Diseases: Alzheimer's and Parkinson's Diseases
Salari, S., & Bagheri, M. (2024) · The Neuroscience Journal of Shefaye Khatam · doi:10.61186/shefa.12.4.81 · Cited by 4
Neurodegenerative disorders: From clinicopathology convergence to systems biology divergence
Fasano, M., & Alberio, T. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85538-9.00007-9 · Cited by 6
A Review of Animal Models of Alzheimer's Disease: a brief insight to Pharmacologic and genetic models
Salari, S., & Bagheri, M. (2016) · Research Repository Portal (Ilam University of Medical Sciences) · Cited by 4
Naturally occurring Alzheimer’s disease in rhesus monkeysPreprint
Li, Z., He, X., Wu, S., Huang, R., Li, H., Wang, Z., Wang, L., Qin, D., Kong, Y., Guo, Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.20.513120 · Cited by 5
Cognitive and affective models of psychedelics in rodents
Anderson, D., & Robinson, E. S. J. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.02.002 · Cited by 3
EFEK GAMBIR (UNCARIA GAMBIR/HUNTER ROXB) TERHADAP AKTIVITAS LOKOMOTOR DAN NEUROKOGNITIF PADA TIKUS BETINA MODEL ALZHEIMER
Fasrini, U. U., Susanti, R., & Lipoeto, N. I. (2017) · Majalah Kedokteran Neurosains Perhimpunan Dokter Spesialis Saraf Indonesia · doi:10.52386/neurona.v35i1.37 · Cited by 3
α7-Nicotinic Acetylcholine Receptors and β-Amyloid Peptides in Alzheimer’s Disease
Lorke, D. E., Petroianu, G. A., & Öz, M. (2016) · Neuromethods · doi:10.1007/978-1-4939-3768-4_10 · Cited by 3
Human Autopsy-Derived Scalp Fibroblast Biobanking for Age-Related Neurodegenerative Disease Research
Beh, S. T., Frisch, C., Brafman, D. A., Churko, J. M., Walker, J. E., Serrano, G. E., Sue, L. I., Reiman, E. M., Beach, T. G., & Lue, L. (2020) · Cells · doi:10.3390/cells9112383 · Cited by 3
Sustained Hippocampal Neural Plasticity Questions the Reproducibility of an Amyloid-β-Induced Alzheimer’s Disease Model
Paulo, S. L., Ribeiro‐Rodrigues, L., Rodrigues, R. S., Mateus, J. M., Fonseca‐Gomes, J., Soares, R., Diógenes, M. J., Solá, S., Sebastião, A. M., Ribeiro, F. F., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201567 · Cited by 2
Tetrahydroxy Stilbene Glycoside Reduces Abeta Deposition by Modulating Microglia Activation and via TREM2/PI3K/AKT Pathway in APP/PS1 Mice
Li, M., Song, Q., Jie, S., Wang, C., Zhang, C., Chi, K., Gao, Y., & Li, T. (2025) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70008 · Cited by 2
Efficacy of Stem Cell-derived Extracellular Vesicles in the Treatment of Alzheimer's Disease Model Mice: A Systematic Review and Meta-analysis
Zheng, Q., Wang, S., Wang, T., & Zhang, G. (2025) · Current Stem Cell Research & Therapy · doi:10.2174/011574888x352270250407170235 · Cited by 2
A Mouse Model of Alzheimer’s Disease with Transplanted Stem-Cell-Derived Human Neurons
Zhu, Y., & Zhang, H. (2017) · Neuroscience Bulletin · doi:10.1007/s12264-017-0180-8 · Cited by 2
Genotype and Sex Differences in Longevity in Transgenic Mouse Models of Alzheimer’s Disease
Brown, R. E., Shin, S., Woodland, N., & Rae, E. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811353-0.00042-7 · Cited by 2
Neuroprotective effects of carnitinoid compounds in rodent cellular and in vivo models of mitochondrial complex I dysfunction
Hoffman, M. E., Augsburger, B. N., Foradori, C. D., Parameshwaran, K., Helsper, S., Marable, J., Steliou, K., Pinkert, C. A., & Irwin, M. H. (2019) · OpenBU (Boston University) · Cited by 2
Animal models of Alzheimer’s Disease
Morgan, D. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0053 · Cited by 2
Uniting homeostatic plasticity and exosome biology: A revision of the conceptual framework for drug discovery in neurodegenerative diseases?
Wang, J. K. T. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.10.002 · Cited by 1
Aging alters the vulnerability pattern to amyloid-beta oligomers in wild-type mice: a behavioral and neurobiological study
Allouche, A., Colin, J., Birck, C., Schroeder, H., Tallandier, V., Baldoni, M., Muller, C., Afrassi, M., & Violle, N. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02051-2 · Cited by 1
Alzheimer’s Disease: A Search for the Best Experimental Models for the Decoding of the Cellular and Molecular Mechanisms of the Development of the Diease
Gorina, Y. V., Власова, О. Л., Bolshakova, A. V., & Salmina, A. B. (2023) · Российский физиологический журнал им И М Сеченова · doi:10.31857/s0869813923010065 · Cited by 1
The Generation of Two Induced Pluripotent Cell Lines from Patients with an Atypical Familial Form of Lung Fibrosis
Mutairy, E. A., Qattan, S. M. A., Imtiaz, F., Alanazi, A., Inglis, A. L., Al‐Rabiah, R. K., & Al-Hijailan, R. S. (2025) · Cells · doi:10.3390/cells14110781 · Cited by 1
Tau Phosphorylation as a Therapeutic Target in Alzheimer’s Disease
Medina, M., & Ávila, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00012-5 · Cited by 1
Environmental enrichment as a preventative and therapeutic approach to Alzheimer's disease
Stuart, K. E., King, A. E., & Vickers, J. C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815854-8.00043-4 · Cited by 1
Challenges and ethical considerations for using cloned primates for human brain discovery
Trounson, A. O., & French, A. J. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1540585 · Cited by 1
Assessing the Relationship of White Matter Hyperintensities and Grey Matter to Neuropsychiatric Symptoms in Alzheimer's Disease and Mild Cognitive Impairment
Misquitta, K. (2017) · TSpace (University of Toronto)
Determining the Validity of Preclinical Behavioral Assessments for Extrapolation to a Clinical Setting
Talpos, J. C., & Chelonis, J. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809405-1.00028-6
Discovery-Based Transcriptome and Translatome Profiling Reveals Molecular Pathways in the Pathogenesis of Alzheimer’s Disease
McKeever, P. M. (2018) · TSpace (University of Toronto)
Conventional Behavioral Models and Readouts in Drug Discovery: The Importance of Improving Translation
Rutten, K. (2021) · Modern CNS Drug Discovery · doi:10.1007/978-3-030-62351-7_5 · Cited by 1
Urozmaicenie środowiska myszy i szczurów w badaniach naukowych
Biała, D., & Kowalczyk, P. K. (2022) · Kosmos · doi:10.36921/kos.2022_2803
The annoying flaws of gerontological research
Khaidakov, M., Troshina, V., Menglet, D., Yusef, Y. N., & Plotkin, A. (2022) · Drug Metabolism Reviews · doi:10.1080/03602532.2022.2035393
Banxia Xiexin Decoction Ameliorates Cognition Deficits by Activating Autophagy-induced Clearance of Aβ in APP/PS1 MicePreprint
Gao, C., Gong, Z., Tian, M., Qin, G., Zheng, M., He, Y., & Wang, P. (2022) · Research Square · doi:10.21203/rs.3.rs-1574557/v1
Alzheimer’s disease as a syndrome of overloaded amyloidic synaptic tagging in memory networksPreprint
Murphy, N. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/7gsaz
Mechanistic Insight into Chronic Stress-Induced Cerebrovascular Dysfunction
Burrage, E. N. (2022) · doi:10.33915/etd.11610
Alzheimer’s Disease: a Search for the Best Experimental Models to Decode Cellular and Molecular Mechanisms of Its Development
Gorina, Y. V., Власова, О. Л., Bolshakova, A. V., & Salmina, A. B. (2023) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093023010106
Alzheimer's Disease In Vivo Models: A Traditional Review
TÜTÜNCÜ, S., Yalçın, H. T., ÖZYURT, A. B., Yirün, A., Baydar, T., & Erkekoğlu, P. (2023) · Journal of Literature Pharmacy Sciences · doi:10.5336/pharmsci.2022-90431

Authors: Puzzo, D., Gulisano, W., Palmeri, A., & Arancio, O.
Affiliations: University of Catania (IT)
Columbia University (US)
ORCID: Puzzo, Daniela
Gulisano, Walter
Palmeri, Agostino
Arancio, Ottavio
Venue: Expert Opinion on Drug Discovery
Publisher: Informa UK Limited
Published: 2015-04-30
Volume: 10
Issue: 7
Pages: 703-711
ISSN: 1746-0441 (ISSN-L)
1746-045X
DOI: 10.1517/17460441.2015.1041913
PMC: PMC4592281
OpenAlex: W1963514255
Cited by: 222
References: 91
Citations by year: 2026: 11 · 2025: 18 · 2024: 13 · 2023: 24 · 2022: 19 · 2021: 25 · 2020: 16 · 2019: 19 · 2018: 30 · 2017: 22 · 2016: 22 · 2015: 3
FWCI: 3.16
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Expert Opinion on Drug Discovery (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute on Aging (R01AG034248, AG034248)
National Institute of Neurological Disorders and Stroke (R01NS049442, NS49442)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: Alzheimer's disease, animal models, transgenic mice, APP/PS1 double transgenic mice, amyloid-beta, tau protein, amyloid plaques, neurofibrillary tangles, presenilin 1, amyloid precursor protein, physiological aging, drug discovery, preclinical testing
MeSH terms: Aging, Alzheimer Disease, Animals, Disease Models, Animal, Drug Evaluation, Preclinical, Humans, Mice, Transgenic, Rodentia, Species Specificity, Mice, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rodent models for Alzheimer’s disease drug discovery

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks